Published in Hepatitis Weekly, December 7th, 1998
MCV was one of a dozen sites in the United States participating in the clinical study, funded by F. Hoffmann-LaRoche Ltd. The study followed 155 hepatitis C patients for 48 weeks, 20 of them through MCV.
Results of the trial showed that while patients were taking the pegylated interferon, two-thirds lost all trace of the virus. Twenty-four weeks after ending treatment, 36 percent still had undetectable levels.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly